28 Nov 2020

Covid 19 Vaccine development and commercialization status | More than 50 vaccine candidate under development

Posted Byadmin

Comments0

More than 50 covid-19 vaccine candidate is currently under development. Here you can have the close look into the development status of the vaccine candidate.

Click here to view

Covid19 vaccine development

SL No.:

Covid-19 Vaccine Candidate:

Sponsor:

Codevelopment Institution:

Mechanism / Key Features:

Development Phase:

SL No.	Covid-19 Vaccine Candidate	Sponsor	Codevelopment Institution	Mechanism / Key Features	Development Phase
1	AZD1222	The University of Oxford; AstraZeneca; IQVIA; Serum Institute of India	The University of Oxford, the Jenner Institute	Replication-deficient viral vector vaccine (adenovirus from chimpanzees)	Phase 3
2	BNT162	Pfizer, BioNTech	Multiple study sites in Europe and North America	mRNA-based vaccine	Phase 3
3	mRNA-1273	Moderna	Kaiser Permanente Washington Health Research Institute	mRNA-based vaccine	Phase 3
4	Ad5-nCoV	CanSino Biologics	Tongji Hospital; Wuhan, China	Recombinant vaccine (adenovirus type 5 vector)	Phase 3
5	CoronaVac	Sinovac	Sinovac Research and Development Co., Ltd.	Inactivated vaccine (formalin with alum adjuvant)	Phase 3
6	Covaxin	Bharat Biotech; National Institute of Virology		Inactivated vaccine	Phase 3
7	JNJ-78436735 (formerly Ad26.COV2.S)	Johnson & Johnson	Johnson & Johnson	Non-replicating viral vector	Phase 3
8	No name announced	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Henan Provincial Center for Disease Control and Prevention	Inactivated vaccine	Phase 3
9	NVX-CoV2373	Novavax	Novavax	Nanoparticle vaccine	Phase 3
10	Sputnik V	Gamaleya Research Institute, Acellena Contract Drug Research and Development	Various	Non-replicating viral vector	Phase 3
11	Bacillus Calmette-Guerin (BCG) vaccine	University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	Live-attenuated vaccine	Phase 2/3
12	INO-4800	Inovio Pharmaceuticals	Center for Pharmaceutical Research, Kansas City. Mo.; University of Pennsylvania, Philadelphia	DNA vaccine (plasmid)	Phase 2/3
13	VIR-7831	Medicago; GSK; Dynavax	Medicago	Plant-based adjuvant vaccine	Phase 2/3
14	No name announced	Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences	Various	Recombinant vaccine	Phase 2
15	ZyCoV-D	Zydus Cadila	Zydus Cadila	DNA vaccine (plasmid)	Phase 2
16	No name announced			Adjuvanted protein subunit vaccine	Phase 1/2
17	AG0301-COVID19	AnGes, Inc.	AnGes, Inc.; Japan Agency for Medical Research and Development	DNA vaccine	Phase 1/2
18	BBIBP-CorV	Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Henan Provincial Center for Disease Control and Prevention	Inactivated vaccine	Phase 1/2
19	EpiVacCorona	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology	Peptide vaccine	Phase 1/2
20	GX-19	Genexine		DNA vaccine	Phase 1/2
21	LNP-nCoVsaRNA	Imperial College London	Imperial College London	Self-amplifying RNA vaccine	Phase 1/2
22	ARCT-021 (LUNAR-COV19)	Arcturus Therapeutics and Duke-NUS Medical School	Duke-NUS Medical School, Singapore	Self-replicating RNA vaccine	Phase 1/2
23	No name announced	Sanofi; GlaxoSmithKline	Various	Protein subunit vaccine	Phase 1/2
24	No name announced	Chinese Academy of Medical Sciences, Institute of Medical Biology	West China Second University Hospital, Yunnan Center for Disease Control and Prevention	Inactivated vaccine	Phase 1/2
25	AdimrSC-2f	Adimmune	Adimmune	Protein subunit vaccine	Phase 1
26	bacTRL-Spike	Symvivo	Symvivo Corporation	Monovalent oral vaccine (bifidobacteria)	Phase 1
27	COVAX-19	Vaxine Pty Ltd.	Royal Adelaide Hospital	Monovalent recombinant protein vaccine	Phase 1
28	CVnCoV	CureVac	CureVac	mRNA-based vaccine	Phase 1
29	DelNS1-2019-nCoV-RBD-OPT1	Xiamen University, Beijing Wantai Biological Pharmacy	Jiangsu Provincial Centre For Disease Control and Prevention	Replicating viral vector	Phase 1
30	GRAd-COV2	ReiThera; Leukocare; Univercells	Lazzaro Spallanzani National Institute for Infectious Diseases	Adenovirus-based vaccine	Phase 1
31	UQ-CSL V451	CSL; The University of Queensland		Protein subunit vaccine	Phase 1
32	No name announced	ImmunityBio; NantKwest		Adenovirus-based vaccine	Phase 1
33	SCB-2019	GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax; CEPI	Linear Clinical Research (Australia)	Protein subunit vaccine	Phase 1
34	UB-612	COVAXX	United Biomedical Inc. (UBI)	Multitope peptide-based vaccine	Phase 1
35	V590	Merck; IAVI		Recombinant vaccine (vesicular stomatitis virus)	Phase 1
36	V591	University of Pittsburgh’s Center for Vaccine Research	University of Pittsburgh; Themis Biosciences; Institut Pasteur	Measles vector vaccine	Phase 1
37	VXA-CoV2-1	Vaxart	Vaxart	Recombinant vaccine (adenovirus type 5 vector)	Phase 1
38	AAVCOVID	Massachusetts Eye and Ear; Massachusetts General Hospital; University of Pennsylvania		Gene-based vaccine	Pre-clinical
39	AdCOVID	Altimmune	University of Alabama at Birmingham	Intranasal vaccine	Pre-clinical
40	ChAd-SARS-CoV-2-S	Washington University School of Medicine in St. Louis	Washington University School of Medicine in St. Louis	Adenovirus-based vaccine	Pre-clinical
41	HaloVax	Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc.	MGH Vaccine and Immunotherapy Center	Self-assembling vaccine	Pre-clinical
42	HDT-301	University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp		RNA vaccine	Pre-clinical
43	LineaDNA	Takis Biotech	Takis Biotech	DNA vaccine	Pre-clinical
44	MRT5500	Sanofi, Translate Bio		Recombinant vaccine	Pre-clinical
45	No name announced	Generex Biotechnology	Generex	Ii-Key peptide COVID-19 vaccine	Pre-clinical
46	No name announced	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre	Protein subunit vaccine	Pre-clinical
47	No name announced	Chulalongkorn University’s Center of Excellence in Vaccine Research and Development		mRNA-based vaccine	Pre-clinical
48	No name announced	Heat Biologics	University of Miami Miller School of Medicine	gp96-based vaccine	Pre-clinical
49	No name announced	Shenzhen Kangtai Biological Products		Inactivated vaccine	Pre-clinical
50	PittCoVacc	UPMC/University of Pittsburgh School of Medicine	University of Pittsburgh	Recombinant protein subunit vaccine (delivered through microneedle array)	Pre-clinical
51	T-COVIDTM	Altimmune		Intranasal vaccine	Pre-clinical
SL No.	Covid-19 Vaccine Candidate	Sponsor	Codevelopment Institution	Mechanism / Key Features	Development Phase

Till date following 2 vaccine candidate is approved.

1. Sputnik V – formerly known as Gam-COVID-Vac and developed by the Gamaleya Research Institute in Moscow – was approved by the Ministry of Health of the Russian Federation on 11 August.

2. EpiVacCorona